• Clinical/real-world application of PK activators in thalassemia
• Novel mechanistic studies supporting PK activation as a treatment target for thalassemia
• Mortality in non-transfusion-dependent thalassemia, healthcare resource utilization, and progression from non-transfusion-dependent to transfusion-dependent thalassemia
• Quality of life measures in both non-transfusion-dependent and transfusion-dependent thalassemia
• Alpha-thalassemia burden of disease
• Characteristics of alpha and beta thalassemia in neonatal and pediatric populations